PaxMedica (NASDAQ: PXMD) is a clinical-stage biopharmaceutical company focused on the development of novel anti-purinergic therapies (“APTs”) for the treatment of autism spectrum disorder (“ASD”) and other serious conditions with intractable neurologic symptoms. The company is on a promising path to address unmet medical needs of ASD patients. “The prevalence of ASD in the United States has risen to approximately 1 in 36 children, according to the Centers for Disease Control and Prevention (‘CDC’). There are currently no approved pharmacologic treatments that target the causes and symptoms of ASD – the treatment available on the market addresses symptoms of the condition rather than targeting the pathophysiology itself,” a recent article explains. “PaxMedica intends to continue into 2024 with the momentum it has gained with its achievements during the past year. The company is building a robust product pipeline to allow people with ASD to successfully integrate their behavior with others and improve their lives. Its lead programs, PAX-101 and PAX-102, utilize the company’s proprietary source of suramin sodium, a broadly acting APT known for over 100 years.”
To view the full article, visit https://ibn.fm/5dpN8
About PaxMedica Inc.
PaxMedica is a forward-looking clinical-stage biopharmaceutical firm specializing in cutting-edge anti-purinergic drug therapies (“APT”) aimed at addressing a range of challenging neurologic disorders, including autism spectrum disorder (“ASD”) and human African trypanosomiasis (“HAT”). Its portfolio encompasses critical areas within the neurology field, with a focus on pioneering advancements in both ASD and HAT treatments. The company is dedicated to the continuous development and evaluation of its pioneering program, PAX-101-an intravenous suramin formulation that lies at the heart of its efforts, particularly focused on innovative ASD and HAT treatment solutions. PaxMedica’s ongoing research initiatives not only prioritize the needs of ASD and HAT patients but also extend to exploring potential therapeutic applications for related conditions. For more information about the company, visit www.PaxMedica.com.
NOTE TO INVESTORS: The latest news and updates relating to PXMD are available in the company’s newsroom at https://ibn.fm/PXMD
About MissionIR
MissionIR (“MIR”) is a specialized communications platform with a focus on assisting IR firms with syndicated content to enhance the visibility of private and public companies within the investment community. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, MIR is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, MIR brings its clients unparalleled recognition and brand awareness.
MIR is where breaking news, insightful content and actionable information converge.
For more information, please visit www.MissionIR.com
Please see full terms of use and disclaimers on the MissionIR website applicable to all content provided by MIR, wherever published or re-published: https://www.MissionIR.com/Disclaimer
MissionIR
Los Angeles, CA
www.MissionIR.com
310.299.1717 Office
Editor@MissionIR.com
MissionIR is powered by IBN
